[English] 日本語
Yorodumi Papers
- Database of articles cited by EMDB/PDB/SASBDB data -

+
Search query

Keywords
Structure methods
Author
Journal
IF

-
Structure paper

TitleCrystal Structure of a human FABP4 complex
Journal, issue, pagesTo be published
Publish dateApr 27, 2023 (structure data deposition date)
AuthorsObst, U. / Magnone, C. / Kuhn, B. / Rudolph, M.G.
External linksSearch PubMed
MethodsX-ray diffraction
Resolution0.88 - 2.6 Å
Structure data

PDB-7fvu:
Crystal Structure of human FABP4 in complex with 2-[2-(benzothiophen-3-yl)-2,3-dihydrobenzothiophene-3-carbonyl]benzoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.24 Å

PDB-7fvv:
Crystal Structure of human FABP4 in complex with (1S,2R)-2-[(5-carbamoyl-3-ethoxycarbonyl-4-methyl-2-thienyl)carbamoyl]cyclohexanecarboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.08 Å

PDB-7fvw:
Crystal Structure of human FABP4 in complex with 2-[2-(3-chlorophenyl)ethyl]-1,3-thiazole-4-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.04 Å

PDB-7fvx:
Crystal Structure of human FABP4 in complex with 4-(1-methyl-2-phenylindol-3-yl)cyclohexane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fvy:
Crystal Structure of human FABP4 in complex with 2-[(3-chlorophenyl)methyl]-1,3-thiazole-4-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1 Å

PDB-7fw0:
Crystal Structure of human FABP4 in complex with 3-methyl-2-(2,4,5-trichlorophenyl)sulfanylbutanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fw1:
Crystal Structure of human FABP4 in complex with 2-cyclopentyl-4-(4-fluorophenyl)-6-[1-(methoxymethyl)cyclopentyl]-3-methyl-5-(1H-tetrazol-5-yl)pyridine
Method: X-RAY DIFFRACTION / Resolution: 1.26 Å

PDB-7fw2:
Crystal Structure of human FABP4 in complex with 5-[(4-chlorophenoxy)methyl]-4-prop-2-enyl-1,2,4-triazole-3-thiol
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fw3:
Crystal Structure of human FABP4 in complex with 7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.08 Å

PDB-7fw4:
Crystal Structure of human FABP4 soaked with glycerol
Method: X-RAY DIFFRACTION / Resolution: 1.44 Å

PDB-7fw5:
Crystal Structure of human FABP4 with active site mutated to that of FABP3 in complex with palmitate
Method: X-RAY DIFFRACTION / Resolution: 1.15 Å

PDB-7fw6:
Crystal Structure of human FABP4 in complex with 2-[(3-chlorophenoxy)methyl]-4-phenoxycyclohexane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.04 Å

PDB-7fw7:
Crystal Structure of human FABP4 in complex with 2-[(3-chloro-4-fluorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.06 Å

PDB-7fw9:
Crystal Structure of human FABP4 in complex with 2-[(3-ethoxycarbonyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1 Å

PDB-7fwa:
Crystal Structure of human FABP4 in complex with 5-[(4-chloroanilino)methyl]-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
Method: X-RAY DIFFRACTION / Resolution: 1.07 Å

PDB-7fwb:
Crystal Structure of human FABP4 in complex with 5-[2-(2,4-dichlorophenoxy)phenyl]-1H-tetrazole
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fwc:
Crystal Structure of human FABP4 in complex with 5-(4-chlorophenyl)-2-(hydroxymethylene)cyclohexane-1,3-dione
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fwd:
Crystal Structure of human FABP4 in complex with 3-[1-(4-carbamoylphenyl)-5-(4-fluorophenyl)pyrrol-2-yl]propanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fwe:
Crystal Structure of human FABP4 in complex with 3-(4-chlorophenyl)sulfanylbutanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fwg:
Crystal Structure of human FABP4 in complex with 1-[(4-chloro-3-phenoxyphenyl)methyl]-4-hydroxypyridin-2-one
Method: X-RAY DIFFRACTION / Resolution: 1.13 Å

PDB-7fwh:
Crystal Structure of human FABP4 in complex with 3-[5-(3,5-dichlorophenyl)tetrazol-2-yl]propanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fwj:
Crystal Structure of human FABP4 in complex with 5-cyclohexyl-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.08 Å

PDB-7fwk:
Crystal Structure of human FABP4 in complex with 1-[(2-chlorophenyl)methyl]pyrrole-2-carboxamide
Method: X-RAY DIFFRACTION / Resolution: 0.95 Å

PDB-7fwl:
Crystal Structure of human FABP4 in complex with 5-[(3,4-dichlorophenyl)methyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fwn:
Crystal Structure of human FABP4 in complex with 3-(5-methyl-2,3-diphenylindol-1-yl)propanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fwo:
Crystal Structure of human FABP4 in complex with 2-cyclohexyl-6-hydroxy-1-benzofuran-3-one
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fwp:
Crystal Structure of human FABP4 in complex with 3-hydroxy-4-[3-(3-methoxyphenyl)propyl]-2-(2-phenylethyl)-2H-furan-5-one
Method: X-RAY DIFFRACTION / Resolution: 1.03 Å

PDB-7fwr:
Crystal Structure of human FABP4 in complex with 3-[(3,4-dichlorophenyl)methylsulfanyl]-1,2,4-triazin-5-ol
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fws:
Crystal Structure of human FABP4 covalently modified with 1,2-benzothiazol-3-one
Method: X-RAY DIFFRACTION / Resolution: 1.1 Å

PDB-7fwu:
Crystal Structure of human FABP4 in complex with 2-(fluoren-9-ylidenemethyl)-4-hydroxy-2,3-dihydropyran-6-one
Method: X-RAY DIFFRACTION / Resolution: 1.01 Å

PDB-7fww:
Crystal Structure of human FABP4 in complex with (3-bromophenyl)-[(2Z)-2-phenylimino-1,3-thiazepan-3-yl]methanone
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fwy:
Crystal Structure of human FABP4 in complex with 2-[(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-6-yl)sulfanyl]acetic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fwz:
Crystal Structure of human FABP4 in complex with 4-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-1-yl]butanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fx0:
Crystal Structure of human FABP4 in complex with 5-[(2-chloroanilino)methyl]-4-ethyl-1,2,4-triazole-3-thiol
Method: X-RAY DIFFRACTION / Resolution: 1.03 Å

PDB-7fx1:
Crystal Structure of human FABP4 in complex with 2-(3-phenyl-4-piperidin-1-ylphenyl)acetic acid
Method: X-RAY DIFFRACTION / Resolution: 0.99 Å

PDB-7fx4:
Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-[(3,4-dichlorophenoxy)methyl]cyclohexane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7fx5:
Crystal Structure of human FABP4 in complex with 5-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-5,7-dihydro-4H-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-4-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fx6:
Crystal Structure of human FABP4 in complex with N,N-diethyl-4-pyridin-4-yl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-amine
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fx7:
Crystal Structure of human FABP4 with binding site mutated to FABP5 in complex with 5-methylsulfanyl-2-[(4-phenylmethoxy-1H-indazol-3-yl)methylsulfanyl]pyrimidin-4-ol
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fx8:
Crystal Structure of human FABP4 in complex with 4-(2-methylpropyl)-2-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fx9:
Crystal Structure of human FABP4 in complex with 2-(3-cyanoanilino)benzoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.1 Å

PDB-7fxa:
Crystal Structure of human FABP4 in complex with 6-bromo-4-hexyl-2-oxo-1,3-dihydroquinoline-4-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fxb:
Crystal Structure of human FABP4 in complex with 2-methyl-2-(2,3,4,5,6-pentachlorophenoxy)propanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fxc:
Crystal Structure of human FABP4 in complex with 6-[(3,4-dichlorophenyl)methyl]-5-methyl-1,1-dioxo-1,2,6-thiadiazin-3-one
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fxe:
Crystal Structure of human FABP4 in complex with 2-(9-benzyl-6-methyl-1,2,3,4-tetrahydrocarbazol-1-yl)acetic acid
Method: X-RAY DIFFRACTION / Resolution: 1.04 Å

PDB-7fxf:
Crystal Structure of human FABP4 in complex with 2-[(2-chlorophenoxy)methyl]-1,3-thiazole-4-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 0.95 Å

PDB-7fxg:
Crystal Structure of human FABP4 in complex with 2-chloro-4,6-bis(trifluoromethylsulfanyl)phenol
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fxh:
Crystal Structure of human FABP4 in complex with 2-[(2R)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7fxi:
Crystal Structure of human FABP4 in complex with rac-(1R,3S)-2,2-dimethyl-3-[(2-phenylphenyl)carbamoyl]cyclopropane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.51 Å

PDB-7fxj:
Crystal Structure of human FABP4 in complex with 1-[(4-chlorophenyl)methyl]-3,4-dihydroxy-2H-pyrrol-5-one
Method: X-RAY DIFFRACTION / Resolution: 1.03 Å

PDB-7fxk:
Crystal Structure of human FABP4 in complex with 5-benzyl-4-(2,5-dimethylpyrrol-1-yl)-1,2,4-triazole-3-thiol
Method: X-RAY DIFFRACTION / Resolution: 1.03 Å

PDB-7fxm:
Crystal Structure of human FABP4 in complex with 5-cyclohexyl-2-hydroxybenzoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.19 Å

PDB-7fxn:
Crystal Structure of human FABP4 in complex with 2-[(2S)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7fxp:
Crystal Structure of human FABP4 in complex with (Z)-4-(4-bromo-2-chloroanilino)-4-oxobut-2-enoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fxq:
Crystal Structure of human FABP4 in complex with 2-(5,6,7,8,9,10-hexahydrobenzo[8]annulen-3-yl)acetic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fxr:
Crystal Structure of human FABP4 in complex with 2-[rac-(9R,10S)-10-benzyl-3,3-dimethyl-1,5-dioxaspiro[5.5]undecan-9-yl]acetic acid
Method: X-RAY DIFFRACTION / Resolution: 0.99 Å

PDB-7fxt:
Crystal Structure of human FABP4 in complex with N-(2,1,3-benzothiadiazol-4-yl)-2,5-dichlorothiophene-3-sulfonamide
Method: X-RAY DIFFRACTION / Resolution: 1.07 Å

PDB-7fxu:
Crystal Structure of human FABP4 in complex with 2-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl]cyclopentene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.96 Å

PDB-7fxv:
Crystal Structure of human FABP4 in complex with 6-[(4-methoxyphenyl)methyl]-2H-1,2,4-triazine-3,5-dithione
Method: X-RAY DIFFRACTION / Resolution: 0.88 Å

PDB-7fxw:
Crystal Structure of human FABP4 in complex with 5,6-dichloro-3-(2-chlorophenyl)-1H-indole-2-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.18 Å

PDB-7fxy:
Crystal Structure of human FABP4 in complex with (4-chlorophenyl)methyl 5-fluoro-2,4-dioxo-1H-pyrimidine-6-carboxylate
Method: X-RAY DIFFRACTION / Resolution: 1.13 Å

PDB-7fxz:
Crystal Structure of human FABP4 in complex with 4-hexylsulfanyl-1-(3-pyridylmethyl)-6-sulfanyl-1,3,5-triazin-2-one
Method: X-RAY DIFFRACTION / Resolution: 1.03 Å

PDB-7fy2:
Crystal Structure of human FABP4 in complex with 2-chloro-5-pyrrol-1-ylbenzoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fy5:
Crystal Structure of human FABP4 in complex with 2,5,5-trimethyl-6,7,8,9-tetrahydrobenzo[7]annulene-3-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fy6:
Crystal Structure of human FABP4 in complex with 6-phenyl-11H-pyrimido[4,5-c][2]benzazepin-3-amine
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fy7:
Crystal Structure of human FABP4 in complex with 2-(indole-1-carbonylamino)benzoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fyb:
Crystal Structure of human FABP4 in complex with rac-(1R,2S,4R)-2-[(3-chlorobenzoyl)amino]-4-phenoxycyclohexane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fyc:
Crystal Structure of human FABP4 in complex with (2R)-1-[(2-phenylphenyl)carbamoyl]pyrrolidine-2-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.08 Å

PDB-7fye:
Crystal Structure of human FABP4 in complex with 1-[(4-chlorophenyl)methyl]-4-hydroxypyridin-2-one
Method: X-RAY DIFFRACTION / Resolution: 1.25 Å

PDB-7fyf:
Crystal Structure of human FABP4 in complex with 4-(4-fluorophenyl)-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7fyg:
Crystal Structure of human FABP4 in complex with 6-benzyl-2H-1,2,4-triazine-3,5-dithione
Method: X-RAY DIFFRACTION / Resolution: 0.94 Å

PDB-7fyi:
Crystal Structure of human FABP4 in complex with 5-[(4-chlorophenyl)sulfanylmethyl]-2-methylpyrazol-3-ol
Method: X-RAY DIFFRACTION / Resolution: 1.14 Å

PDB-7fyj:
Crystal Structure of human FABP4 in complex with 5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
Method: X-RAY DIFFRACTION / Resolution: 2.6 Å

PDB-7fyk:
Crystal Structure of human FABP4 in complex with 5-phenylmethoxy-4-prop-2-enyl-1,2,4-triazole-3-thiol
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fyl:
Crystal Structure of human FABP4 in complex with 6-(4-chlorophenyl)sulfanyl-2-(4-methylphenyl)sulfanylhexanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.07 Å

PDB-7fyo:
Crystal Structure of human FABP4 in complex with 5-(3,5-dichloroanilino)-3,3-dimethyl-5-oxopentanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fyp:
Crystal Structure of human FABP4 in complex with (1S,2S)-2-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxycarbonylcyclopropane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fyq:
Crystal Structure of human FABP4 in complex with 2-(3,5-ditert-butyl-2-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxypropanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fyr:
Crystal Structure of human FABP4 in complex with 5-(3,4-dichlorophenyl)-5-methyl-2-sulfanylidene-1,3-diazinane-4,6-dione
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fys:
Crystal Structure of human FABP4 in complex with 7-(4-methoxyphenyl)-1,8-dithia-3-azaspiro[4.5]dec-6-ene-2,4-dione
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fyt:
Crystal Structure of human FABP4 in complex with 5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
Method: X-RAY DIFFRACTION / Resolution: 1.24 Å

PDB-7fyu:
Crystal Structure of human FABP4 in complex with 2-benzyl-6-tert-butyl-3-methyl-4-phenyl-5-(1H-tetrazol-5-yl)pyridine
Method: X-RAY DIFFRACTION / Resolution: 1.17 Å

PDB-7fyv:
Crystal Structure of human FABP4 in complex with 5-(4-chlorophenyl)-9-methyl-3-oxa-4-azatricyclo[5.2.1.02,6]dec-4-ene-8-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 0.97 Å

PDB-7fyx:
Crystal Structure of human FABP4 in complex with 2-[(3-phenylthiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.4 Å

PDB-7fyy:
Crystal Structure of human FABP4 in complex with 5,7-bis(trifluoromethylsulfanyl)quinolin-8-ol
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fyz:
Crystal Structure of human FABP4 in complex with 2-[2,3-bis[(2-chlorophenyl)methoxy]phenyl]-2-methoxyacetic acid
Method: X-RAY DIFFRACTION / Resolution: 1.13 Å

PDB-7fz0:
Crystal Structure of human FABP4 in complex with 2-tert-butyl-6-ethyl-4,5-diphenyl-3-(1H-tetrazol-5-yl)pyridine
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7fz1:
Crystal Structure of human FABP4 in complex with 3-[(E)-anilino-(2-oxo-1H-indol-3-ylidene)methyl]sulfanylpropanoic acid
Method: X-RAY DIFFRACTION / Resolution: 0.99 Å

PDB-7fz2:
Crystal Structure of human FABP4 in complex with [3-oxo-5-[4-(trifluoromethyl)phenyl]cyclohexen-1-yl] acetate
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fz3:
Crystal Structure of human FABP4 in complex with 4-(4-chlorophenoxy)benzenesulfinic acid:sodium hydride
Method: X-RAY DIFFRACTION / Resolution: 1.1 Å

PDB-7fz4:
Crystal Structure of human FABP4 in complex with 6-(difluoromethyl)-4-isobutyl-5-methoxycarbonyl-2-(trifluoromethyl)pyridine-3-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.01 Å

PDB-7fz5:
Crystal Structure of human FABP4 in complex with rac-(2R)-1-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]pyrrolidine-2-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.25 Å

PDB-7fz6:
Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-(phenoxymethyl)cyclohexane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.09 Å

PDB-7fz7:
Crystal Structure of human FABP4 in complex with 2-[2-[(2-chlorophenyl)methyl]-1-hydroxycyclohexyl]acetic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fz8:
Crystal Structure of human FABP4 in complex with thieno[2,3-d]pyrimidine-2,4-diamine
Method: X-RAY DIFFRACTION / Resolution: 1.22 Å

PDB-7fz9:
Crystal Structure of human FABP4 in complex with N-methyl-6-(3-methylthiophen-2-yl)-4-phenyl-N-propan-2-yl-3-(1H-tetrazol-5-yl)pyridin-2-amine
Method: X-RAY DIFFRACTION / Resolution: 0.96 Å

PDB-7fzb:
Crystal Structure of human FABP4 in complex with 2-[5-methyl-2-(1-methylcyclohexyl)-1,3-oxazol-4-yl]acetic acid
Method: X-RAY DIFFRACTION / Resolution: 1.08 Å

PDB-7fzc:
Crystal Structure of human FABP4 in complex with 5-[(2-chlorophenoxy)methyl]-4-propan-2-yl-1,2,4-triazole-3-thiol
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fzd:
Crystal Structure of human FABP4 in complex with 3-(4-chlorophenyl)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,2]oxazole-5-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7fzf:
Crystal Structure of human FABP4 in complex with 2-(6-methyl-4-oxo-5-phenylthieno[2,3-d]pyrimidin-3-yl)butanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.09 Å

PDB-7fzh:
Crystal Structure of human FABP4 in complex with 4-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-5,7-dihydro-4H-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-5-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fzi:
Crystal Structure of human FABP4 in complex with 2-[[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.07 Å

PDB-7fzj:
Crystal Structure of human FABP4 in complex with 3-cyclohexyl-2-ethylsulfanyl-6-hydroxypyrimidin-4-one
Method: X-RAY DIFFRACTION / Resolution: 1.25 Å

PDB-7fzl:
Crystal Structure of human FABP4 in complex with 3-(3-chlorophenyl)-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fzm:
Crystal Structure of human FABP4 in complex with N-(2,4-dichlorophenyl)-2-(2,6-dihydroxypyrimidin-4-yl)acetamide
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7fzn:
Crystal Structure of human FABP4 in complex with (1S,2S,5R)-3-(2-thiophen-3-ylacetyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fzo:
Crystal Structure of human FABP4 in complex with 4-oxo-3-(2-phenylethyl)-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-6-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 0.99 Å

PDB-7fzp:
Crystal Structure of human FABP4 in complex with 6-[(4-chlorophenyl)methylsulfanylmethyl]-2-sulfanylidene-1H-pyrimidin-4-one
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fzr:
Crystal Structure of human FABP4 in complex with 4-hydroxy-6-(2-naphthalen-1-ylethyl)pyran-2-one
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7fzs:
Crystal Structure of human FABP4 in complex with 6-chloro-4-[(2-chlorophenyl)methyl]-2-methylquinoline-3-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.04 Å

PDB-7fzv:
Crystal Structure of human FABP4 in complex with 1-[(2,4-dichlorophenyl)methyl]-4-hydroxy-3-[(E)-3-phenylprop-2-enyl]pyridin-2-one
Method: X-RAY DIFFRACTION / Resolution: 2.55 Å

PDB-7fzw:
Crystal Structure of human FABP4 in complex with 2-[[5-bromo-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.24 Å

PDB-7fzx:
Crystal Structure of human FABP4 in complex with (2S)-6-(4-chlorophenoxy)-2-(4-methylphenoxy)hexanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.07 Å

PDB-7fzy:
Crystal Structure of human FABP4 in complex with 6-chloro-4-phenyl-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)quinoline
Method: X-RAY DIFFRACTION / Resolution: 1.17 Å

PDB-7fzz:
Crystal Structure of human FABP4 in complex with 3-[(2,4-dichloro-5-methylphenyl)sulfonylamino]thiophene-2-carboxamide
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g02:
Crystal Structure of human FABP4 in complex with 7-methoxy-1-(3-methoxyphenyl)naphthalene-2-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.03 Å

PDB-7g03:
Crystal Structure of human FABP4 in complex with 6-fluoro-1,3-benzothiazol-2-amine
Method: X-RAY DIFFRACTION / Resolution: 1.27 Å

PDB-7g05:
Crystal Structure of human FABP4 in complex with 2,6-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenol
Method: X-RAY DIFFRACTION / Resolution: 0.95 Å

PDB-7g06:
Crystal Structure of human FABP4 in complex with 5-(chloromethyl)-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
Method: X-RAY DIFFRACTION / Resolution: 1.26 Å

PDB-7g07:
Crystal Structure of human FABP4 in complex with 4-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-5-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.61 Å

PDB-7g08:
Crystal Structure of human FABP4 in complex with 2-(3-chloro-2-methylanilino)benzoic acid
Method: X-RAY DIFFRACTION / Resolution: 0.99 Å

PDB-7g09:
Crystal Structure of human FABP4 in complex with 8-(3-bromophenyl)-7,9-dioxa-1-thia-3-azaspiro[4.5]decane-2,4-dione
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7g0a:
Crystal Structure of human FABP4 in complex with 5-(6-chloro-4-phenyl-2-piperidin-1-ylquinolin-3-yl)-3H-1,3,4-oxadiazol-2-one
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g0f:
Crystal Structure of human FABP4 in complex with 6-[(3-methoxycarbonyl-4-thiophen-2-ylthiophen-2-yl)carbamoyl]cyclohex-3-ene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g0g:
Crystal Structure of human FABP4 in complex with 5-(3-bromo-4-methylphenyl)-3,3-dimethyl-5-oxopentanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g0h:
Crystal Structure of human FABP4 in complex with (2R,3S)-2-(phenoxymethyl)-1-phenyl-pyrrolidine-3-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.46 Å

PDB-7g0i:
Crystal Structure of human FABP4 in complex with 5-phenoxy-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.07 Å

PDB-7g0j:
Crystal Structure of human FABP4 in complex with 2-[3-(4-chloro-2-phenoxyphenyl)phenyl]acetic acid
Method: X-RAY DIFFRACTION / Resolution: 1.08 Å

PDB-7g0k:
Crystal Structure of human FABP4 in complex with (2R)-1-[(3,5-dichloro-2-phenylphenyl)carbamoyl]pyrrolidine-2-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.13 Å

PDB-7g0l:
Crystal Structure of human FABP4 in complex with 3-[(4-methyl-3-phenoxyphenyl)methyl]-1H-pyrazol-5-ol
Method: X-RAY DIFFRACTION / Resolution: 1.18 Å

PDB-7g0m:
Crystal Structure of human FABP4 in complex with 2-tert-butylsulfanyl-6-phenyl-1H-1,3,5-triazine-4-thione
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7g0p:
Crystal Structure of human FABP4 in complex with 3-[(4-phenyl-5-sulfanylidene-1,3,4-thiadiazol-2-yl)sulfanyl]propane-1-sulfonic acid
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7g0q:
Crystal Structure of human FABP4 in complex with 4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7g0r:
Crystal Structure of human FABP4 in complex with 4-methoxy-1,2-benzoxazol-3-amine
Method: X-RAY DIFFRACTION / Resolution: 1.03 Å

PDB-7g0s:
Crystal Structure of human FABP4 in complex with 2,3-bis(phenylmethoxy)benzoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7g0t:
Crystal Structure of human FABP4 in complex with 1-[[4-chloro-2-(trifluoromethyl)phenyl]carbamoylamino]cyclopentane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.65 Å

PDB-7g0u:
Crystal Structure of human FABP4 in complex with 5-[(3-chlorophenyl)methyl]-6-hydroxy-1-methyl-4-morpholin-4-ylpyrimidin-2-one
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g0v:
Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-[[3-(trifluoromethyl)phenoxy]methyl]cyclohexane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.06 Å

PDB-7g0y:
Crystal Structure of human FABP4 in complex with 2-(2-methoxyanilino)benzoic acid
Method: X-RAY DIFFRACTION / Resolution: 0.99 Å

PDB-7g11:
Crystal Structure of human FABP4 in complex with 2,4,6-triisopropylbenzenesulfonic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g14:
Crystal Structure of human FABP4 in complex with 6-cyclopentyl-N,5-dimethyl-4-phenyl-N-propan-2-yl-3-(1H-tetrazol-5-yl)pyridin-2-amine
Method: X-RAY DIFFRACTION / Resolution: 1.2 Å

PDB-7g16:
Crystal Structure of human FABP4 in complex with 6-bromo-3-hexyl-2-oxo-3,4-dihydro-1H-quinoline-4-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.1 Å

PDB-7g17:
Crystal Structure of human FABP4 in complex with 2-(1H-indol-7-yloxymethyl)-1,3-thiazole-4-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.05 Å

PDB-7g18:
Crystal Structure of human FABP4 in complex with 4-(4-chloro-3-fluorophenoxy)-2-(3,4-dichlorophenyl)-2-methylbutanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g19:
Crystal Structure of human FABP4 in complex with 5-[2-(1H-tetrazol-5-yl)ethyl]-6,7,8,9,10,11-hexahydrocycloocta[b]indole
Method: X-RAY DIFFRACTION / Resolution: 1.04 Å

PDB-7g1a:
Crystal Structure of human FABP4 in complex with 2-[(3S)-oxolan-3-yl]oxy-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g1b:
Crystal Structure of human FABP4 in complex with 2-[1-[(3-chlorophenyl)methyl]indol-2-yl]cyclopropane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.17 Å

PDB-7g1c:
Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-[(3-methylphenoxy)methyl]cyclohexane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.08 Å

PDB-7g1d:
Crystal Structure of human FABP4 in complex with 5-ethyl-6-(3-methoxyphenyl)-3-methyl-2-sulfanylidene-1H-pyrimidin-4-one
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g1e:
Crystal Structure of human FABP4 in complex with 3-[(2-phenylphenoxy)methyl]benzoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.21 Å

PDB-7g1f:
Crystal Structure of human FABP4 in complex with 1-(4-methylphenyl)sulfonyl-3-(8-tricyclo[5.2.1.02,6]decanyl)urea
Method: X-RAY DIFFRACTION / Resolution: 0.91 Å

PDB-7g1g:
Crystal Structure of human FABP4 in complex with 2-(2-hydroxy-3,5,5,8,8-pentamethyl-3,4,4a,6,7,8a-hexahydro-1H-naphthalen-2-yl)acetic acid
Method: X-RAY DIFFRACTION / Resolution: 1.03 Å

PDB-7g1h:
Crystal Structure of human FABP4 in complex with 2-(3,5-ditert-butyl-2-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxypropanoic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g1i:
Crystal Structure of human FABP4 in complex with 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.53 Å

PDB-7g1j:
Crystal Structure of human FABP4 in complex with 2-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl]cyclohexene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.11 Å

PDB-7g1k:
Crystal Structure of human FABP4 in complex with 4-(4-fluorophenyl)sulfanyl-6-methyl-2-phenylpyrimidine-5-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g1l:
Crystal Structure of human FABP4 in complex with 6-(1,3-benzodioxol-5-ylmethyl)-3-sulfanyl-1,2,4-triazin-5-ol
Method: X-RAY DIFFRACTION / Resolution: 0.98 Å

PDB-7g1n:
Crystal Structure of human FABP4 in complex with rac-(1R,2R)-2-[[3-(3-methyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]cyclohexane-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.55 Å

PDB-7g1o:
Crystal Structure of human FABP4 in complex with 4-chloro-2,5-dimethyl-N-(2-methylpyrazol-3-yl)benzenesulfonamide
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g1r:
Crystal Structure of human FABP4 in complex with 2-[(3-ethoxycarbonylthiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 0.93 Å

PDB-7g1s:
Crystal Structure of human FABP4 in complex with 3-(3,4-dichlorophenyl)-3,7a-dihydro-1H-imidazo[1,5-c][1,3]thiazole-5,7-dione
Method: X-RAY DIFFRACTION / Resolution: 1.08 Å

PDB-7g1t:
Crystal Structure of human FABP4 in complex with 6-methyl-3-phenyl-1,2,4-triazin-5-ol
Method: X-RAY DIFFRACTION / Resolution: 1.1 Å

PDB-7g1u:
Crystal Structure of human FABP4 in complex with 2-[[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.14 Å

PDB-7g1v:
Crystal Structure of human FABP4 in complex with 3-[(2-sulfanylphenyl)carbamoyl]bicyclo[2.2.1]heptane-2-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 1.02 Å

PDB-7g1y:
Crystal Structure of human FABP4 in complex with 2-[(3-methoxyphenyl)sulfanylmethyl]-1,3-thiazole-4-carboxylic acid
Method: X-RAY DIFFRACTION / Resolution: 0.95 Å

PDB-7g1z:
Crystal Structure of human FABP4 in complex with 5-[(4-chloro-3-phenoxyphenyl)methyl]-1H-tetrazole
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g20:
Crystal Structure of human FABP4 in complex with 1-[(4-methoxyphenyl)methyl]-5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-7g21:
Crystal Structure of human FABP4 in complex with 4-hydroxy-2-[(E)-2-(2-phenylcyclohexyl)ethenyl]-2,3-dihydropyran-6-one
Method: X-RAY DIFFRACTION / Resolution: 1.12 Å

PDB-8s1k:
Crystal Structure of human FABP4 in complex with 2-[1-(methoxymethyl)cyclopentyl]-6-pentyl-4-phenyl-3-(1H-tetrazol-5-yl)-5,6,7,8-tetrahydroquinoline
Method: X-RAY DIFFRACTION / Resolution: 1.22 Å

Chemicals

ChemComp-SO4:
SULFATE ION

ChemComp-GFS:
2-[(2S,3R)-2,3-dihydro[2,3'-bi-1-benzothiophene]-3-carbonyl]benzoic acid

ChemComp-HOH:
WATER

ChemComp-IOV:
(1R,2S)-2-{[5-carbamoyl-3-(ethoxycarbonyl)-4-methylthiophen-2-yl]carbamoyl}cyclohexane-1-carboxylic acid

ChemComp-IQH:
2-[2-(3-chlorophenyl)ethyl]-1,3-thiazole-4-carboxylic acid

ChemComp-FMT:
FORMIC ACID

ChemComp-IUT:
(1s,4s)-4-(1-methyl-2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acid

ChemComp-IWI:
2-[(3-chlorophenyl)methyl]-1,3-thiazole-4-carboxylic acid

ChemComp-K0U:
(2R)-3-methyl-2-[(2,4,5-trichlorophenyl)sulfanyl]butanoic acid

ChemComp-K7C:
(5P)-2-cyclopentyl-4-(4-fluorophenyl)-6-[1-(methoxymethyl)cyclopentyl]-3-methyl-5-(1H-tetrazol-5-yl)pyridine

ChemComp-KCV:
5-[(4-chlorophenoxy)methyl]-4-(prop-2-en-1-yl)-4H-1,2,4-triazole-3-thiol

ChemComp-DMS:
DIMETHYL SULFOXIDE / DMSO, precipitant*YM

ChemComp-KL3:
(1R)-7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid

ChemComp-GOL:
GLYCEROL

ChemComp-PLM:
PALMITIC ACID

ChemComp-KLX:
(1R,2S,4S)-2-[(3-chlorophenoxy)methyl]-4-phenoxycyclohexane-1-carboxylic acid

ChemComp-KWX:
(1S,2S)-2-[(3-chloro-4-fluorophenyl)carbamoyl]cyclohexane-1-carboxylic acid

ChemComp-L8T:
2-{[3-(ethoxycarbonyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-LE5:
(8S)-5-[(4-chloroanilino)methyl]-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one

ChemComp-LM9:
(5P)-5-[2-(2,4-dichlorophenoxy)phenyl]-2H-tetrazole

ChemComp-M69:
(2seqTrans,5S)-5-(4-chlorophenyl)-2-(hydroxymethylidene)cyclohexane-1,3-dione

ChemComp-M8I:
3-[1-(4-carbamoylphenyl)-5-(4-fluorophenyl)-1H-pyrrol-2-yl]propanoic acid

ChemComp-MF9:
(3S)-3-[(4-chlorophenyl)sulfanyl]butanoic acid

ChemComp-MWR:
1-[(4-chloro-3-phenoxyphenyl)methyl]-4-hydroxypyridin-2(1H)-one

ChemComp-N1I:
3-[5-(3,5-dichlorophenyl)-2H-tetrazol-2-yl]propanoic acid

ChemComp-MQF:
5-cyclohexyl-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid

ChemComp-76Y:
1-[(2-chlorophenyl)methyl]pyrrole-2-carboxamide

ChemComp-O6Q:
5-[(3,4-dichlorophenyl)methyl]-1lambda~6~,2,5-thiadiazolidine-1,1,3-trione

ChemComp-OKF:
3-(5-methyl-2,3-diphenyl-1H-indol-1-yl)propanoic acid

ChemComp-OM6:
(2S)-2-cyclohexyl-6-hydroxy-1-benzofuran-3(2H)-one

ChemComp-OT9:
(5R)-4-hydroxy-3-[3-(3-methoxyphenyl)propyl]-5-(2-phenylethyl)furan-2(5H)-one

ChemComp-P6X:
3-{[(3,4-dichlorophenyl)methyl]sulfanyl}-1,2,4-triazin-5-ol

ChemComp-PV6:
2-sulfanylbenzamide

ChemComp-Q0O:
(6S)-6-{[(4aM)-9H-fluoren-9-ylidene]methyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one

ChemComp-Q6I:
(3-bromophenyl)[(2Z)-2-(phenylimino)-1,3-thiazepan-3-yl]methanone

ChemComp-QBX:
{[(10R)-2-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl]sulfanyl}acetic acid

ChemComp-QD3:
4-[3-(trifluoromethyl)-5,6,7,8-tetrahydrocyclohepta[c]pyrazol-1(4H)-yl]butanoic acid

ChemComp-QG0:
5-[(2-chloroanilino)methyl]-4-ethyl-4H-1,2,4-triazole-3-thiol

ChemComp-QJD:
[6-(piperidin-1-yl)[1,1'-biphenyl]-3-yl]acetic acid

ChemComp-Q29:
(1R,2S)-2-[(3,4-dichlorophenoxy)methyl]cyclohexane-1-carboxylic acid

ChemComp-Q4X:
5-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}-3,6-dihydro-2H-pyran-4-carboxylic acid

ChemComp-CL:
Unknown entry

ChemComp-QJX:
(3M)-N,N-diethyl-4-(pyridin-4-yl)-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-amine

ChemComp-QLL:
2-({[4-(benzyloxy)-1H-indazol-3-yl]methyl}sulfanyl)-5-(methylsulfanyl)pyrimidin-4-ol

ChemComp-EDO:
1,2-ETHANEDIOL

ChemComp-QN6:
(3M)-4-(2-methylpropyl)-2-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

ChemComp-QX0:
2-(3-cyanoanilino)benzoic acid

ChemComp-QYP:
(4S)-6-bromo-4-hexyl-2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid

ChemComp-QZI:
2-methyl-2-(pentachlorophenoxy)propanoic acid

ChemComp-R80:
(5S)-6-[(3,4-dichlorophenyl)methyl]-5-methyl-1lambda~6~,2,6-thiadiazinane-1,1,3-trione

ChemComp-R9C:
[(1S)-9-benzyl-6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid

ChemComp-R9O:
2-[(2-chlorophenoxy)methyl]-1,3-thiazole-4-carboxylic acid

ChemComp-RG6:
2-chloro-4,6-bis[(trifluoromethyl)sulfanyl]phenol

ChemComp-RI4:
(3P)-2-[(2R)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

ChemComp-RJM:
(1S,3R)-3-[([1,1'-biphenyl]-2-yl)carbamoyl]-2,2-dimethylcyclopropane-1-carboxylic acid

ChemComp-S4I:
(3S)-1-[(4-chlorophenyl)methyl]-3-hydroxypyrrolidine-2,4-dione

ChemComp-S8X:
5-benzyl-4-(2,5-dimethyl-1H-pyrrol-1-yl)-4H-1,2,4-triazole-3-thiol

ChemComp-KWB:
5-cyclohexyl-2-hydroxybenzoate

ChemComp-SUX:
(3P)-2-[(2S)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

ChemComp-TB3:
(2Z)-4-(4-bromo-2-chloroanilino)-4-oxobut-2-enoic acid

ChemComp-TK6:
(5,6,7,8,9,10-hexahydrobenzo[8]annulen-2-yl)acetic acid

ChemComp-TQO:
[(8R,9S)-8-benzyl-3,3-dimethyl-1,5-dioxaspiro[5.5]undecan-9-yl]acetic acid

ChemComp-TZJ:
N-(2,1,3-benzothiadiazol-4-yl)-2,5-dichlorothiophene-3-sulfonamide

ChemComp-U6O:
2-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-U8H:
6-[(4-methoxyphenyl)methyl]-1,2,4-triazine-3,5(2H,4H)-dithione

ChemComp-UB8:
(3M)-5,6-dichloro-3-(2-chlorophenyl)-1H-indole-2-carboxylic acid

ChemComp-UKN:
(4-chlorophenyl)methyl 5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate

ChemComp-UO3:
4-hexylsulfanyl-1-(pyridin-3-ylmethyl)-6-sulfanyl-1$l^{4},3,5-triazacyclohexa-1,3,5-trien-2-ol

ChemComp-UOR:
2-chloro-5-(1H-pyrrol-1-yl)benzoic acid

ChemComp-V4R:
3,9,9-trimethyl-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid

ChemComp-VI0:
(10S)-10-phenyl-10,11-dihydro-5H-pyrimido[4,5-c][2]benzazepin-2-amine

ChemComp-NC0:
2-[(2,3-dihydro-1H-indole-1-carbonyl)amino]benzoic acid

ChemComp-VIY:
(1R,2S,4R)-2-(3-chlorobenzamido)-4-phenoxycyclohexane-1-carboxylic acid

ChemComp-VJ3:
1-[([1,1'-biphenyl]-2-yl)carbamoyl]-D-proline

ChemComp-VMN:
1-[(4-chlorophenyl)methyl]-4-hydroxypyridin-2(1H)-one

ChemComp-VS5:
(3M)-4-(4-fluorophenyl)-2-(piperidin-1-yl)-3-(1H-tetrazol-5-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine

ChemComp-VVL:
6-benzyl-1,2,4-triazine-3,5(2H,4H)-dithione

ChemComp-W7U:
(5R)-3-{[(4-chlorophenyl)sulfanyl]methyl}-1-methyl-4,5-dihydro-1H-pyrazol-5-ol

ChemComp-W7Z:
(8S)-5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one

ChemComp-W8C:
5-(benzyloxy)-4-(prop-2-en-1-yl)-4H-1,2,4-triazole-3-thiol

ChemComp-W8H:
(2S)-6-[(4-chlorophenyl)sulfanyl]-2-[(4-methylphenyl)sulfanyl]hexanoic acid

ChemComp-W90:
5-(3,5-dichloroanilino)-3,3-dimethyl-5-oxopentanoic acid

ChemComp-W95:
(1S,2S)-2-({[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy}carbonyl)cyclopropane-1-carboxylic acid

ChemComp-W9B:
(2R)-2-(3,5-di-tert-butyl-2-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxypropanoic acid

ChemComp-W9F:
5-(3,4-dichlorophenyl)-5-methyl-2-sulfanylidene-1,3-diazinane-4,6-dione

ChemComp-W9K:
(5R)-7-(4-hydroxyphenyl)-1,8-dithia-3-azaspiro[4.5]dec-6-ene-2,4-dione

ChemComp-UUX:
(2R,3S,4S)-6-benzyl-2-tert-butyl-5-methyl-4-phenyl-3-(1H-tetrazol-5-yl)-1,2,3,4-tetrahydropyridine

ChemComp-W9Q:
(3aR,4R,5R,6S,7R,7aR)-3-(4-chlorophenyl)-6-methyl-3a,4,5,6,7,7a-hexahydro-4,7-methano-1,2-benzoxazole-5-carboxylic acid

ChemComp-W9W:
2-{[(4R)-4-phenyl-3,4-dihydro-2H-1lambda~4~-thiophen-5-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-WA4:
5,7-bis[(trifluoromethyl)sulfanyl]quinolin-8-ol

ChemComp-WA9:
(2R)-{2,3-bis[(2-chlorophenyl)methoxy]phenyl}(methoxy)acetic acid

ChemComp-EOH:
ETHANOL

ChemComp-WBR:
(3P)-2-tert-butyl-6-ethyl-4,5-diphenyl-3-(1H-tetrazol-5-yl)pyridine

ChemComp-WDE:
3-{[(E)-anilino(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]sulfanyl}propanoic acid

ChemComp-WDI:
(1S)-5-hydroxy-4'-(trifluoromethyl)-1,6-dihydro[1,1'-biphenyl]-3(2H)-one

ChemComp-WDO:
1-[bis(oxidanyl)-$l^{3}-sulfanyl]-4-(4-chloranylphenoxy)benzene

ChemComp-WE2:
6-(difluoromethyl)-5-(methoxycarbonyl)-4-(2-methylpropyl)-2-(trifluoromethyl)pyridine-3-carboxylic acid

ChemComp-WE6:
1-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}-D-proline

ChemComp-WEA:
(1S,2R)-2-(phenoxymethyl)cyclohexane-1-carboxylic acid

ChemComp-WED:
{(1R,2S)-2-[(2-chlorophenyl)methyl]-1-hydroxycyclohexyl}acetic acid

ChemComp-WEI:
thieno[2,3-d]pyrimidine-2,4-diamine

ChemComp-WER:
(3M,6P)-N-methyl-6-(3-methylthiophen-2-yl)-4-phenyl-N-(propan-2-yl)-3-(1H-tetrazol-5-yl)pyridin-2-amine

ChemComp-WEN:
[5-methyl-2-(1-methylcyclohexyl)-1,3-oxazol-4-yl]acetic acid

ChemComp-WF6:
5-[(2-chlorophenoxy)methyl]-4-(propan-2-yl)-4H-1,2,4-triazole-3-thiol

ChemComp-WFC:
(3aS,5R,6aS)-3-(4-chlorophenyl)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,2]oxazole-5-carboxylic acid

ChemComp-WFK:
(1R,3R,4S)-3-(4-chlorobenzoyl)-4-hydroxycyclopentane-1-carboxylic acid

ChemComp-WFO:
(2R)-2-(6-methyl-4-oxo-5-phenylthieno[2,3-d]pyrimidin-3(4H)-yl)butanoic acid

ChemComp-WFX:
4-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}-5,6-dihydro-2H-pyran-3-carboxylic acid

ChemComp-WG3:
2-{[(2M)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-WGL:
1-cyclohexyl-2-(ethylsulfanyl)pyrimidine-4,6(1H,5H)-dione

ChemComp-WGQ:
(5P)-5-(3-chlorophenyl)-4-(prop-2-en-1-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

ChemComp-WGW:
N-(2,4-dichlorophenyl)-2-(2,6-dioxo-1,2,5,6-tetrahydropyrimidin-4-yl)acetamide

ChemComp-WHB:
(1R,2S,5S)-3-[(thiophen-3-yl)acetyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid

ChemComp-WH3:
(3aR,6S,7R,7aS)-1-oxo-2-(2-phenylethyl)-1,2,3,6,7,7a-hexahydro-3a,6-epoxyisoindole-7-carboxylic acid

ChemComp-WHI:
6-({[(4-chlorophenyl)methyl]sulfanyl}methyl)-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one

ChemComp-WHN:
4-hydroxy-6-[2-(naphthalen-1-yl)ethyl]-2H-pyran-2-one

ChemComp-WHR:
6-chloro-4-[(2-chlorophenyl)methyl]-2-methylquinoline-3-carboxylic acid

ChemComp-O1L:
1-[(2,4-dichlorophenyl)methyl]-4-hydroxy-3-[(2E)-3-phenylprop-2-en-1-yl]pyridin-2(1H)-one

ChemComp-WI8:
2-{[(2M)-5-bromo-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-BR:
BROMIDE ION

ChemComp-WIC:
(2S)-6-(4-chlorophenoxy)-2-(4-methylphenoxy)hexanoic acid

ChemComp-65X:
6-chloro-4-phenyl-2-(piperidin-1-yl)-3-(1H-tetrazol-5-yl)quinoline

ChemComp-TRS:
2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL / pH buffer*YM

ChemComp-WIF:
3-[(2,4-dichloro-5-methylbenzene-1-sulfonyl)amino]thiophene-2-carboxamide

ChemComp-WIL:
(1M)-7-methoxy-1-(3-methoxyphenyl)naphthalene-2-carboxylic acid

ChemComp-PG4:
TETRAETHYLENE GLYCOL / precipitant*YM

ChemComp-FBB:
6-fluoro-1,3-benzothiazol-2-amine

ChemComp-WJ3:
2,6-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenol

ChemComp-WJ8:
(8S)-5-(chloromethyl)-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one

ChemComp-WJH:
4-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}-5,6-dihydro-2H-pyran-3-carboxylic acid

ChemComp-TLF:
2-[(3-chloro-2-methylphenyl)amino]benzoic acid / antiinflammatory, inhibitor*YM

ChemComp-WJQ:
(5s,8s)-8-(3-bromophenyl)-7,9-dioxa-1-thia-3-azaspiro[4.5]decane-2,4-dione

ChemComp-WJU:
(5M)-5-[6-chloro-4-phenyl-2-(piperidin-1-yl)quinolin-3-yl]-1,3,4-oxadiazol-2(3H)-one

ChemComp-WK9:
(1R,2S)-2-{[(2M)-4'-(methoxycarbonyl)-4,5-dihydro-2'H,3H-[2,3'-bi-1lambda~4~-thiophen]-5'-yl]carbamoyl}cyclohexane-1-carboxylic acid

ChemComp-W8N:
5-(3-bromo-4-methylphenyl)-3,3-dimethyl-5-oxopentanoic acid

ChemComp-W8T:
(2R,3S)-2-(phenoxymethyl)-1-phenylpyrrolidine-3-carboxylic acid

ChemComp-TXO:
5-phenoxy-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid

ChemComp-WKI:
[(1M)-4'-chloro-2'-phenoxy[1,1'-biphenyl]-3-yl]acetic acid

ChemComp-UOF:
1-[(4,6-dichloro[1,1'-biphenyl]-2-yl)carbamoyl]-D-proline

ChemComp-WKN:
3-[(4-methyl-3-phenoxyphenyl)methyl]-1H-pyrazol-5-ol

ChemComp-WKR:
4-(tert-butylsulfanyl)-6-phenyl-1,3,5-triazine-2(5H)-thione

ChemComp-WL0:
3-[(4-phenyl-5-sulfanylidene-4,5-dihydro-1,3,4-thiadiazol-2-yl)sulfanyl]propane-1-sulfonic acid

ChemComp-WL6:
4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid

ChemComp-5WX:
4-methoxy-1,2-benzoxazol-3-amine

ChemComp-UNU:
BENZAMIDE

ChemComp-WLB:
2,3-bis(benzyloxy)benzoic acid

ChemComp-WLF:
1-{[4-chloro-2-(trifluoromethyl)phenyl]carbamamido}cyclopentane-1-carboxylic acid

ChemComp-WLN:
5-[(3-chlorophenyl)methyl]-6-hydroxy-1-methyl-4-(morpholin-4-yl)pyrimidin-2(1H)-one

ChemComp-WLR:
(1S,2R)-2-{[3-(trifluoromethyl)phenoxy]methyl}cyclohexane-1-carboxylic acid

ChemComp-WM5:
2-(2-methoxyanilino)benzoic acid

ChemComp-75D:
2,4,6-tri(propan-2-yl)benzenesulfonic acid

ChemComp-Q1I:
(3P)-6-cyclopentyl-N,5-dimethyl-4-phenyl-N-(propan-2-yl)-3-(1H-tetrazol-5-yl)pyridin-2-amine

ChemComp-WML:
(3S,4R)-6-bromo-3-hexyl-2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid

ChemComp-WMQ:
2-{[(1H-indol-7-yl)oxy]methyl}-1,3-thiazole-4-carboxylic acid

ChemComp-WMW:
(2S)-4-(4-chloro-3-fluorophenoxy)-2-(3,4-dichlorophenyl)-2-methylbutanoic acid

ChemComp-WN0:
5-[2-(1H-tetrazol-5-yl)ethyl]-6,7,8,9,10,11-hexahydro-5H-cycloocta[b]indole

ChemComp-WN5:
(3M)-2-{[(3S)-oxolan-3-yl]oxy}-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

ChemComp-WNB:
(1S,2S)-2-{1-[(3-chlorophenyl)methyl]-1H-indol-2-yl}cyclopropane-1-carboxylic acid

ChemComp-WNF:
(1S,2R)-2-[(3-methylphenoxy)methyl]cyclohexane-1-carboxylic acid

ChemComp-WNL:
(6M)-5-ethyl-6-(3-methoxyphenyl)-3-methyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one

ChemComp-WNR:
3-{[([1,1'-biphenyl]-2-yl)oxy]methyl}benzoic acid

ChemComp-WNW:
4-methyl-N-{[(3aR,4R,5R,7R,7aR)-octahydro-1H-4,7-methanoinden-5-yl]carbamoyl}benzene-1-sulfonamide

ChemComp-WO0:
[(2S,3S,4aR,8aR)-2-hydroxy-3,5,5,8,8-pentamethyldecahydronaphthalen-2-yl]acetic acid

ChemComp-WOB:
5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid

ChemComp-WKW:
2-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl}cyclohex-1-ene-1-carboxylic acid

ChemComp-WOI:
4-[(4-fluorophenyl)sulfanyl]-6-methyl-2-phenylpyrimidine-5-carboxylic acid

ChemComp-WON:
6-[(2H-1,3-benzodioxol-5-yl)methyl]-3-sulfanyl-1,2,4-triazin-5-ol

ChemComp-WP0:
(1R,2R)-2-{[(3M)-3-(3-methyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}cyclohexane-1-carboxylic acid

ChemComp-WP8:
4-chloro-2,5-dimethyl-N-(1-methyl-1H-pyrazol-5-yl)benzene-1-sulfonamide

ChemComp-WPQ:
2-{[3-(ethoxycarbonyl)thiophen-2-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-WPU:
(3R,4R,7aS)-3-(3,4-dichlorophenyl)-1H,3H-imidazo[1,5-c][1,3]thiazole-5,7(6H,7aH)-dione

ChemComp-WPZ:
6-methyl-3-phenyl-1,2,4-triazin-5-ol

ChemComp-WQ3:
2-{[(2M)-5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-WQ8:
(1R,2R,3R,4S)-3-(1,3-benzothiazol-2-yl)bicyclo[2.2.1]heptane-2-carboxylic acid

ChemComp-WQC:
2-{[(3-methoxyphenyl)sulfanyl]methyl}-1,3-thiazole-4-carboxylic acid

ChemComp-WQH:
5-[(4-methyl-3-phenoxyphenyl)methyl]-1H-tetrazole

ChemComp-WQL:
(5S)-1-[(4-methoxyphenyl)methyl]-5-(propan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione

ChemComp-IKQ:
(6R)-4-hydroxy-6-{(E)-2-[(1R,2S)-2-phenylcyclohexyl]ethenyl}-5,6-dihydro-2H-pyran-2-one

PDB-1h4y:
Structure of the Anti-Sigma Factor Antagonist SpoIIAA in its Unphosphorylated Form

Source
  • homo sapiens (human)
KeywordsLIPID BINDING PROTEIN / FATTY ACID BINDING PROTEIN / CYTOPLASM / LIPID-BINDING / TRANSPORT / PROTEIN BINDING / HUMAN FABP4 / INHIBITOR

+
About Yorodumi Papers

-
News

-
Feb 9, 2022. New format data for meta-information of EMDB entries

New format data for meta-information of EMDB entries

  • Version 3 of the EMDB header file is now the official format.
  • The previous official version 1.9 will be removed from the archive.

Related info.:EMDB header

External links:wwPDB to switch to version 3 of the EMDB data model

-
Aug 12, 2020. Covid-19 info

Covid-19 info

URL: https://pdbj.org/emnavi/covid19.php

New page: Covid-19 featured information page in EM Navigator.

Related info.:Covid-19 info / Mar 5, 2020. Novel coronavirus structure data

+
Mar 5, 2020. Novel coronavirus structure data

Novel coronavirus structure data

Related info.:Yorodumi Speices / Aug 12, 2020. Covid-19 info

External links:COVID-19 featured content - PDBj / Molecule of the Month (242)：Coronavirus Proteases

+
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)

EMDB accession codes are about to change! (news from PDBe EMDB page)

  • The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
  • The EM Navigator/Yorodumi systems omit the EMD- prefix.

Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator

External links:EMDB Accession Codes are Changing Soon! / Contact to PDBj

+
Jul 12, 2017. Major update of PDB

Major update of PDB

  • wwPDB released updated PDB data conforming to the new PDBx/mmCIF dictionary.
  • This is a major update changing the version number from 4 to 5, and with Remediation, in which all the entries are updated.
  • In this update, many items about electron microscopy experimental information are reorganized (e.g. em_software).
  • Now, EM Navigator and Yorodumi are based on the updated data.

External links:wwPDB Remediation / Enriched Model Files Conforming to OneDep Data Standards Now Available in the PDB FTP Archive

-
Yorodumi Papers

Database of articles cited by EMDB/PDB/SASBDB data

  • Database of articles cited by EMDB, PDB, and SASBDB entries
  • Using PubMed data

Related info.:EMDB / PDB / SASBDB / Yorodumi / EMN Papers / Changes in new EM Navigator and Yorodumi

Read more